Nymox Pharmaceutical Corporation

Pharma company announces new patents

Published in Mental Health Business Week, March 26th, 2005

A series of new patents add to the breadth and depth of the product development programs of Nymox Pharmaceutical Corporation (NYMX), according the company's General Counsel, Jack Gemmell.

The company was recently issued U.S. patents for a method of measuring cholesterol levels using saliva and for novel Alzheimer disease drug candidates targeting spherons and an Australian patent for the use of statin drugs to treat or prevent Alzheimer disease. As well, a U.S. patent has issued for a new method of creating animal models for Alzheimer disease using the DNA sequence for neural thread protein (NTP) under license to the company from Rhode Island Hospital affiliated with...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Mental Health Business Week

Source: Mental Health Business Week (2005-03-26)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry